Research ArticleOriginal Article

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy

Zhichao Liao, Ting Li, Chao Zhang, Xinyue Liu, Ruwei Xing, Sheng Teng, Yun Yang, Gang Zhao, Xu Bai, Jun Zhao and Jilong Yang
Cancer Biology & Medicine May 2020, 17 (2) 501-512; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0397

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chen W,
    3. Zheng R,
    4. Baade PD,
    5. Zhang S,
    6. Zeng H,
    7. Bray F, et al.
    Cancer statistics in china, 2015. CA Cancer J Clin. 2016; 66: 115–32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Federman N,
    3. Bernthal N,
    4. Eilber FC,
    5. Tap WD.
    The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009; 10: 82–93.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Xu H,
    3. Huang Z,
    4. Li Y,
    5. Zhang Q,
    6. Hao L,
    7. Niu X.
    Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study. Cancer Biol Med. 2019; 16: 166–72.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Ferrari S,
    3. Briccoli A,
    4. Mercuri M,
    5. Bertoni F,
    6. Picci P,
    7. Tienghi A, et al.
    Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003; 21: 710–5.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Palmerini E,
    3. Jones RL,
    4. Marchesi E,
    5. Paioli A,
    6. Cesari M,
    7. Longhi A, et al.
    Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016; 16: 280.
    OpenUrl
  7. 7.↵
    2. Lamplot JD,
    3. Denduluri S,
    4. Qin J,
    5. Li R,
    6. Liu X,
    7. Zhang H, et al.
    The current and future therapies for human osteosarcoma. Curr Cancer Ther Rev. 2013; 9: 55–77.
    OpenUrl
  8. 8.↵
    2. Longhi A,
    3. Ferrari S,
    4. Bacci G,
    5. Specchia S.
    Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007; 18: 737–44.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Kumar S,
    3. Marfatia R,
    4. Tannenbaum S,
    5. Yang C,
    6. Avelar E.
    Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Tex Heart Inst J. 2012; 39: 424–7.
    OpenUrlPubMed
  10. 10.↵
    2. Kempf-Bielack B,
    3. Bielack SS,
    4. Jurgens H,
    5. Branscheid D,
    6. Berdel WE,
    7. Exner GU, et al.
    Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005; 23: 559–68.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Seto T,
    3. Song MN,
    4. Trieu M,
    5. Yu J,
    6. Sidhu M,
    7. Liu CM, et al.
    Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci (Basel). 2019; 7: 48.
    OpenUrl
  12. 12.↵
    2. Davis LE,
    3. Bolejack V,
    4. Ryan CW,
    5. Ganjoo KN,
    6. Loggers ET,
    7. Chawla S, et al.
    Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019; 37: 1424–31.
    OpenUrl
  13. 13.↵
    2. Xie L,
    3. Xu J,
    4. Sun X,
    5. Tang X,
    6. Yan T,
    7. Yang R, et al.
    Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist. 2019; 24: e542–50.
  14. 14.
    2. Gaspar N,
    3. Casanova M,
    4. Sirvent FJB,
    5. Venkatramani R,
    6. Morland B,
    7. Gambart M, et al.
    Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). J Clin Oncol. 2018; 36: 11527.
    OpenUrl
  15. 15.
    2. Italiano A,
    3. Penel N,
    4. Toulmonde M,
    5. Bompas E,
    6. Piperno-Neumann S,
    7. Pulido M, et al.
    LBA67Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/Us National Cancer Institute phase II collaborative study. Ann Oncol. 2018; 29.
  16. 16.
    2. Zheng K,
    3. Xu M,
    4. Wang L,
    5. Yu X.
    Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: a single-center observational study. Medicine (Baltimore). 2018; 97: e11734.
  17. 17.↵
    2. Grignani G,
    3. Palmerini E,
    4. Dileo P,
    5. Asaftei SD,
    6. D’Ambrosio L,
    7. Pignochino Y, et al.
    A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an italian sarcoma group study. Ann Oncol. 2012; 23: 508–16.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    2. Folkman J.
    Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res. 2006; 312: 594–607.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Li J,
    3. Qin S,
    4. Xu J,
    5. Xiong J,
    6. Wu C,
    7. Bai Y, et al.
    Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016; 34: 1448–54.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    2. Tian S,
    3. Quan H,
    4. Xie C,
    5. Guo H,
    6. Lu F,
    7. Xu Y, et al.
    YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011; 102: 1374–80.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Roviello G,
    3. Ravelli A,
    4. Polom K,
    5. Petrioli R,
    6. Marano L,
    7. Marrelli D, et al.
    Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016; 372: 187–91.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Li J,
    3. Zhao X,
    4. Chen L,
    5. Guo H,
    6. Lv F,
    7. Jia K, et al.
    Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010; 10: 529.
    OpenUrlCrossRefPubMed
  23. 23.
    2. Li J,
    3. Qin S,
    4. Xu J,
    5. Guo W,
    6. Xiong J,
    7. Bai Y, et al.
    Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31: 3219–25.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Hu X,
    3. Zhang J,
    4. Xu B,
    5. Jiang Z,
    6. Ragaz J,
    7. Tong Z, et al.
    Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014; 135: 1961–9.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Dong M,
    3. Bi J,
    4. Liu X,
    5. Wang B,
    6. Wang J.
    Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case report. Medicine (Baltimore). 2016; 95: e4368.
  26. 26.↵
    2. Zhou Y,
    3. Tang F,
    4. Wang Y,
    5. Min L,
    6. Luo Y,
    7. Zhang W, et al.
    Advanced alveolar soft part sarcoma responds to apatinib. Oncotarget. 2017; 8: 50314–22.
    OpenUrl
  27. 27.↵
    2. Li F,
    3. Liao Z,
    4. Zhao J,
    5. Zhao G,
    6. Li X,
    7. Du X, et al.
    Efficacy and safety of apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017; 8: 64471–80.
    OpenUrl
  28. 28.↵
    2. Shi C,
    3. Feng Y,
    4. Zhang LC,
    5. Ding DY,
    6. Yan MY,
    7. Pan L.
    Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review. BMC Cancer. 2018; 18: 338.
    OpenUrl
  29. 29.↵
    2. Zhu B,
    3. Li J,
    4. Xie Q,
    5. Diao L,
    6. Gai L,
    7. Yang W.
    Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018; 19: 198–204.
    OpenUrl
  30. 30.↵
    2. Xie L,
    3. Guo W,
    4. Wang Y,
    5. Yan T,
    6. Ji T,
    7. Xu J.
    Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018; 18: 396.
    OpenUrl
  31. 31.↵
    2. Schwartz LH,
    3. Litiere S,
    4. de Vries E,
    5. Ford R,
    6. Gwyther S,
    7. Mandrekar S, et al.
    RECIST 1.1 – update and clarification: from the RECIST committee. Eur J Cancer. 2016; 62: 132–7.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Eisenhauer EA,
    3. Therasse P,
    4. Bogaerts J,
    5. Schwartz LH,
    6. Sargent D,
    7. Ford R, et al.
    New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228–47.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Burningham Z,
    3. Hashibe M,
    4. Spector L,
    5. Schiffman JD.
    The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2: 14.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Allemani C,
    3. Weir HK,
    4. Carreira H,
    5. Harewood R,
    6. Spika D,
    7. Wang XS, et al.
    Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385: 977–1010.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Liu K,
    3. Ren T,
    4. Huang Y,
    5. Sun K,
    6. Bao X,
    7. Wang S, et al.
    Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017; 8: e3015.
  36. 36.↵
    2. Zheng B,
    3. Ren T,
    4. Huang Y,
    5. Guo W.
    Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun. 2018; 495: 1695–701.
    OpenUrlPubMed
  37. 37.↵
    2. Mori Y,
    3. Kinoshita S,
    4. Kanamori T,
    5. Kataoka H,
    6. Joh T,
    7. Iida S, et al.
    The successful treatment of metastatic extraosseous Ewing sarcoma with pazopanib. Intern Med. 2018; 57: 2753–7.
    OpenUrl
  38. 38.↵
    2. Alcindor T.
    Response of refractory Ewing sarcoma to pazopanib. Acta Oncol. 2015; 54: 1063–4.
    OpenUrl
  39. 39.↵
    2. Maki RG,
    3. D’Adamo DR,
    4. Keohan ML,
    5. Saulle M,
    6. Schuetze SM,
    7. Undevia SD, et al.
    Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133–40.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords